Loading clinical trials...

Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer | Clinical Trials | Clareo Health

TERMINATEDNA

Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer

NCT01875198•Yonsei University

View on ClinicalTrials.gov

Summary

When distal pancreatectomy is carried out for left-sided pancreatic cancer, splenectomy is usually performed not only for margin-negative resection but also for effective clearance of the splenic hilar lymph nodes. However, there was no scientific evidence regarding the justifiability for spleen resection. Considering potential immunological function of the spleen, the investigators hypothesized that distal pancreatectomy without pancreatectomy for left-sided pancreatic cancer is superior than Distal pancreatectomy with pancreatectomy in terms of short-term perioperative outcomes and disease-specific overall survival.

Eligibility

Age

20 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Ductal adenocarcinoma
•2. Age ≥20 and ≤80
•3. General performance status: the Karnofsky score\> 70% or ECOG 0-1
•4. Potentially Curative resection
•5. Tumor size \< 3cm
•6. Pancreatic cancer located on neck or body portion
•7. No invasion to spleen or spleen hilum
•8. No combined resection except Lt. adrenal gland
•9. Distance more than 5cm (≥5cm) between tumor lateral margin and spleen hilum

Exclusion Criteria

•1. Unresectable or locally advanced, metastatic case
•2. Patients who do not want surgery
•3. ASA (American society of anesthesiologists' physical status classification) score: ≥3
•4. Patients with drug or alcohol addiction
•5. Patients showing low compliance
•6. Patients who not want to involve the clinical trial
•7. Patients who are unable to read or understand the informed consent, sign a consent form (eg, mental retardation, blindness, illiteracy, foreign, etc.)

Locations (1)

Severance Hospital

Seoul, Seoul, South Korea

Key Dates

Start Date

April 1, 2013

Primary Completion Date

April 1, 2014

Completion Date

April 1, 2014

Last Updated

November 22, 2016

Enrollment

ACTUAL participants

Conditions

Left-sided Pancreatic CancerDuctal Adenocarcinoma

Interventions

Radical Antegrade Modular Pancreatectomy with Splenectomy

PROCEDURE

Radical Antegrade Modular Pancreatectomy without splenectomy

PROCEDURE

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Advanced CancerMetastatic Cancer+7 more

View study

RECRUITINGPHASE1/PHASE2

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062

Colorectal CancerCRC+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 22, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer

Inclusion Criteria

Exclusion Criteria

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors